Enterprise Value
5.022B
Cash
48.46M
Avg Qtr Burn
N/A
Short % of Float
3.46%
Insider Ownership
57.00%
Institutional Own.
32.55%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
PEMRYDI RTU® Details Small cell lung cancer, Malignant pleural/peritoneal mesothelioma | Approved Update | |
Lisdexamfetamine Dimesylate Details Attention deficit hyperactivity disorder | Approved Quarterly sales | |
RELEUKO® (filgrastim-ayow) Details Chemotherapy-induced neutropenia | Approved Quarterly sales | |
Xyrem® (sodium oxybate) Generic Details Narcolepsy | Approved Quarterly sales | |
OTC NARCAN® HCI Nasal Spray Details Opioid overdose | Approved Quarterly sales | |
IPX203 Details Parkinson's disease | NDA Acceptance for review |